טוען...
Additional low-dose antimuscarinics can improve overactive bladder symptoms in patients with suboptimal response to beta 3 agonist monotherapy
PURPOSE: We aimed to assess the patient-reported outcome (PRO) and efficacy of add-on low-dose antimuscarinic therapy in over-active bladder (OAB) patients with suboptimal response to 4-week treatment with beta 3 agonist monotherapy (mirabegron, 50 mg). MATERIALS AND METHODS: We enrolled OAB patient...
שמור ב:
| הוצא לאור ב: | Investig Clin Urol |
|---|---|
| Main Authors: | , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
The Korean Urological Association
2017
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5494350/ https://ncbi.nlm.nih.gov/pubmed/28681036 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4111/icu.2017.58.4.261 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|